BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Monday, August 5th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last announced its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06. The business had revenue of $92.80 million during the quarter, compared to the consensus estimate of $85.62 million. The business’s revenue was up 34.9% compared to the same quarter last year. During the same period last year, the company earned ($0.28) EPS. On average, analysts expect BioCryst Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
BioCryst Pharmaceuticals Stock Down 1.3 %
Shares of BioCryst Pharmaceuticals stock opened at $7.02 on Friday. The stock’s fifty day moving average is $6.69 and its two-hundred day moving average is $5.77. The company has a market capitalization of $1.45 billion, a PE ratio of -6.56 and a beta of 1.88. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $7.93.
Insider Buying and Selling
Analyst Ratings Changes
BCRX has been the topic of several research analyst reports. JMP Securities upped their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a research report on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. Finally, Needham & Company LLC reissued a “buy” rating and set a $12.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $14.67.
Check Out Our Latest Research Report on BCRX
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
See Also
- Five stocks we like better than BioCryst Pharmaceuticals
- How to Invest in Small Cap Stocks
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- Are Penny Stocks a Good Fit for Your Portfolio?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Evaluate a Stock Before Buying
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.